Study shows AZ+mRNA vaccination regimen is as good as two doses of mRNA
An immunogenicity study, conducted in Germany, shows the mixed use of viral vector and mRNA vaccines induces a significantly high level of anti-spike and neutralizing antibodies, close to the level induced by two doses of mRNA vaccine, according to Professor Dr. Manop Pithukpakorn, head of the Excellence Centre for Genomics and Precision Medicine at Siriraj Hospital.
Dr. Manop cited the immunogenicity study, published in the Nature Medicine journal yesterday (Monday), which was a comparative study between two cohorts, one administered with viral vector AstraZeneca (AZ) and one of the two mRNA vaccines, Pfizer or Moderna, and another administered with two doses of Pfizer or Moderna. The two doses of mRNA vaccine were administered four weeks apart, while the AZ and mRNA doses were administered 11 weeks apart.
Measurement of humoral and cellular immunity in the two cohorts shows the AZ-mRNA mixed use of vaccines induces both anti-spike and neutralizing antibodies at a level which is ten times that of the AZ-AZ regimen and up to the level induced by the mRNA-mRNA regimen.
In a closer look into the study of cellular immunity, mixed use of AZ-mRNA vaccines generates as good an immune response as the use of mRNA-mRNA vaccines, with better results regarding spike-specific IFN-y-producing CD8 T cells.
Dr. Manop said that undesirable side effects from AZ-mRNA vaccine regimen, which were administered 9-12 weeks apart, are less than those from the mRNA-mRNA regimen and are acceptable.
This study in Germany may provide support for an earlier study indicating that the mix and match of AZ as the first dose and mRNA as the second dose might be the right formula for future vaccinations, he added.
Thailand does not yet have an mRNA vaccine, with delivery of about 1.5 million doses of Pfizer vaccine from the US government expected on Thursday (July 29th) and 20 million other doses of Pfizer and 5 million doses of Moderna ordered for deliveries in the fourth quarter of this year. The country has received more than 10 million doses of AZ, mostly locally produced by Thai firm Siam Bioscience to date.